A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
| Status: | Completed |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/23/2013 |
| Start Date: | August 2012 |
| End Date: | April 2015 |
| Contact: | Terri Lowe |
| Email: | clinicaltrials@seagen.com |
| Phone: | 866-333-7436 |
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of
SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell
carcinoma.
Inclusion Criteria:
- Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression
- Previously treated with at least 1 tyrosine kinase inhibitor (TKI)
- Measurable disease
- Eastern Cooperative Oncology Group performance status 0 or 1
- Adequate lung and renal function
Exclusion Criteria:
- Prior treatment with anti-CD70-directed therapy
- Received more than one prior treatment with an mTOR inhibitor
We found this trial at
8
sites
3322 West End Avenue
Nashville, Tennessee 37203
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Stanford University Cancer Institute The Stanford Cancer Institute (SCI) focuses the world-class expertise of more...
Click here to add this to my saved trials